Comparative stability studies of fixed dose combinations of propranolol hydrochloride and flunarizine dihydrochloride by RP-HPLC

Sudheer Kumar Verriboina, Krutika Patel, S. G. Vasantharaju, B. S. Muddukrishna

Research output: Contribution to journalArticle

Abstract

A stability indicating RP-HPLC method was developed for the simultaneous estimation of propranolol hydrochloride and flunarizine dihydrochloride in bulk and various fixed-dose combinations in the presence of its degradation products. The validation of the method was performed as per ICH Q2(R1) and USFDA guidelines. The separation was achieved with a C18-Hibar column at 25 °C, mobile phase containing methanol and 25 mM ammonium formate buffer (pH adjusted to 3.8 with formic acid, 0.1% v/v Triethylamine) (75:25 v/v) at a flow rate of 1 mL/min using Photo Diode Array (PDA) detector at 238 nm. The impacts of pH-dependent hydrolysis (acidic and basic), oxidative stress, thermal stress and photolytic stress conditions on percentage degradation of both drugs were compared in bulk drug and various fixed-dose combinations. The proposed method was found specific, sensitive, and reproducible for routine analysis of propranolol hydrochloride and flunarizine dihydrochloride fixed-dose combinations within 10 min as run time.

Original languageEnglish
Pages (from-to)2448-2457
Number of pages10
JournalLatin American Journal of Pharmacy
Volume37
Issue number12
Publication statusPublished - 01-01-2018

Fingerprint

formic acid
Flunarizine
Propranolol
High Pressure Liquid Chromatography
United States Food and Drug Administration
Pharmaceutical Preparations
Methanol
Buffers
Oxidative Stress
Hydrolysis
Hot Temperature
Guidelines

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Drug Discovery

Cite this

@article{dac547d385aa4a4c84a6a28f5e55fb4d,
title = "Comparative stability studies of fixed dose combinations of propranolol hydrochloride and flunarizine dihydrochloride by RP-HPLC",
abstract = "A stability indicating RP-HPLC method was developed for the simultaneous estimation of propranolol hydrochloride and flunarizine dihydrochloride in bulk and various fixed-dose combinations in the presence of its degradation products. The validation of the method was performed as per ICH Q2(R1) and USFDA guidelines. The separation was achieved with a C18-Hibar column at 25 °C, mobile phase containing methanol and 25 mM ammonium formate buffer (pH adjusted to 3.8 with formic acid, 0.1{\%} v/v Triethylamine) (75:25 v/v) at a flow rate of 1 mL/min using Photo Diode Array (PDA) detector at 238 nm. The impacts of pH-dependent hydrolysis (acidic and basic), oxidative stress, thermal stress and photolytic stress conditions on percentage degradation of both drugs were compared in bulk drug and various fixed-dose combinations. The proposed method was found specific, sensitive, and reproducible for routine analysis of propranolol hydrochloride and flunarizine dihydrochloride fixed-dose combinations within 10 min as run time.",
author = "Verriboina, {Sudheer Kumar} and Krutika Patel and Vasantharaju, {S. G.} and Muddukrishna, {B. S.}",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "37",
pages = "2448--2457",
journal = "Latin American Journal of Pharmacy",
issn = "0326-2383",
publisher = "Colegio de Farmaceuticos de la Provincia de Buenos Aires",
number = "12",

}

Comparative stability studies of fixed dose combinations of propranolol hydrochloride and flunarizine dihydrochloride by RP-HPLC. / Verriboina, Sudheer Kumar; Patel, Krutika; Vasantharaju, S. G.; Muddukrishna, B. S.

In: Latin American Journal of Pharmacy, Vol. 37, No. 12, 01.01.2018, p. 2448-2457.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative stability studies of fixed dose combinations of propranolol hydrochloride and flunarizine dihydrochloride by RP-HPLC

AU - Verriboina, Sudheer Kumar

AU - Patel, Krutika

AU - Vasantharaju, S. G.

AU - Muddukrishna, B. S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A stability indicating RP-HPLC method was developed for the simultaneous estimation of propranolol hydrochloride and flunarizine dihydrochloride in bulk and various fixed-dose combinations in the presence of its degradation products. The validation of the method was performed as per ICH Q2(R1) and USFDA guidelines. The separation was achieved with a C18-Hibar column at 25 °C, mobile phase containing methanol and 25 mM ammonium formate buffer (pH adjusted to 3.8 with formic acid, 0.1% v/v Triethylamine) (75:25 v/v) at a flow rate of 1 mL/min using Photo Diode Array (PDA) detector at 238 nm. The impacts of pH-dependent hydrolysis (acidic and basic), oxidative stress, thermal stress and photolytic stress conditions on percentage degradation of both drugs were compared in bulk drug and various fixed-dose combinations. The proposed method was found specific, sensitive, and reproducible for routine analysis of propranolol hydrochloride and flunarizine dihydrochloride fixed-dose combinations within 10 min as run time.

AB - A stability indicating RP-HPLC method was developed for the simultaneous estimation of propranolol hydrochloride and flunarizine dihydrochloride in bulk and various fixed-dose combinations in the presence of its degradation products. The validation of the method was performed as per ICH Q2(R1) and USFDA guidelines. The separation was achieved with a C18-Hibar column at 25 °C, mobile phase containing methanol and 25 mM ammonium formate buffer (pH adjusted to 3.8 with formic acid, 0.1% v/v Triethylamine) (75:25 v/v) at a flow rate of 1 mL/min using Photo Diode Array (PDA) detector at 238 nm. The impacts of pH-dependent hydrolysis (acidic and basic), oxidative stress, thermal stress and photolytic stress conditions on percentage degradation of both drugs were compared in bulk drug and various fixed-dose combinations. The proposed method was found specific, sensitive, and reproducible for routine analysis of propranolol hydrochloride and flunarizine dihydrochloride fixed-dose combinations within 10 min as run time.

UR - http://www.scopus.com/inward/record.url?scp=85060919589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060919589&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 2448

EP - 2457

JO - Latin American Journal of Pharmacy

JF - Latin American Journal of Pharmacy

SN - 0326-2383

IS - 12

ER -